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Systemic inflammation, resulting from massive release of pro-inflammatory molecules into the 
circulatory system, is a major risk factor for severe illness, but the precise mechanisms underlying 
its control are incompletely understood. We observed that prostaglandin E2 (PGE2) through its 
receptor EP4 is down-regulated in human systemic inflammatory disease. Mice with reduced PGE2 
synthesis develop systemic inflammation, associated with translocation of gut bacteria, which can 
be prevented by treating with EP4 agonists. Mechanistically, we demonstrate that PGE2–EP4 
signaling directly acts on type 3 innate lymphoid cells (ILCs), promoting their homeostasis and 
driving them to produce interleukin-22 (IL-22). Disruption of the ILC/IL-22 axis impairs PGE2–
mediated inhibition of systemic inflammation. Hence, PGE2–EP4 signaling inhibits systemic 
inflammation through ILC/IL-22 axis–dependent protection of gut barrier dysfunction.  
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Systemic inflammation commonly develops from locally invasive infection, is characterized by 
dysregulation of the innate immune system and overproduction of pro-inflammatory cytokines and 
can result in severe critical illness (e.g., bacteremia, sepsis and septic shock) (1,2). Despite much 
research on systemic inflammation, our understanding of the precise mechanisms for its control 
remains incomplete and represents an unmet clinical need (1-3). Prostaglandins (PGs) are bioactive 
lipid mediators generated from arachidonic acid via the enzymatic activity of cyclooxygenases 
(COXs) (4). PGs participate in the pathogenesis of inflammatory disease (4,5) and many 
inflammatory conditions are treated using non-steroidal anti-inflammatory drugs (NSAIDs) that 
inhibit PG synthesis by blocking COXs (6). NSAID therapy is also thought to confer similar 
beneficial effects in treating severe inflammation, but large randomized controlled clinical trials 
have found that NSAIDs failed to reduce mortality in severe systemic inflammation (7,8). More 
importantly, NSAIDs use during evolving bacterial infection is associated with more severe critical 
illness (9-13). Therefore there is an imperative to define the paradoxical regulatory role of PGs in 
systemic inflammation (14). 
 
PGE2 is one of the most abundantly produced PGs and modulates immune and inflammatory 
responses through its receptors (EP1 – 4) (4). We performed a genome-wide gene expression 
analysis of whole blood samples from neonates with sepsis (15) and found that expression of 
PTGES2 (encoding membrane-associated PGE synthase-2) and PTGER4 (encoding EP4) were 
significantly diminished in the sepsis group compared with non-infected controls (Fig. 1A). The 
reduced expression of PTGES2 and PTGER4 was associated with increased neutrophil blood count 
as a marker of inflammation (Fig. 1B). Down-regulation of PTGER4 and PTGS2 (encoding COX2) 
was similarly observed in patients suffering from systemic inflammatory response syndrome, 
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sepsis, septic shock or severe blunt trauma; but in contrast, expression of HPGD (encoding 15-
PGDH which mediates PGE2 degradation) in these patients was up-regulated compared to non-
infected controls (fig. S1). Consistent with this, blood monocytes from patients with sepsis and 
septic shock produced less PGE2 (16). Thus the PGE2–EP4 pathway is down-regulated in human 
severe systemic inflammatory disease.   
 
To understand the mechanism(s) whereby PGE2 regulates systemic inflammation, we challenged 
wild-type (WT) C57BL/6 mice with lipopolysaccharide (LPS) to induce systemic inflammation 
after pre-treatment with indomethacin, which effectively suppresses PGE2 production (17,18). 
Mice pre-treated with indomethacin developed an enhanced cytokine storm (e.g., tumor necrosis 
factor-α (TNF-α) and IL-6) (Fig. 1C) as well as other inflammatory signs in indomethacin-treated 
mice, e.g., splenomegaly (Fig. 1D), peritonitis characterized by accumulation of CD11b+Ly-6G+ 
neutrophils (Fig. 1E), and a low-grade hepatic inflammation as characterized by sinusoidal 
lymphocytosis and necrosis/inflammatory foci in the parenchyma (Fig. 1F). Furthermore, co-
administration of an EP4 agonist almost completely diminished indomethacin-augmented 
systemic inflammation (Fig. 1, G to I). Thus PGE2-EP4 signaling constrains LPS-induced 
systemic inflammation. 
   
Besides the inflammatory markers described above, we also detected dissemination of gut bacteria 
into normally sterile tissues (e.g., liver) of indomethacin-treated, but not control, mice (Fig. 2A). 
The co-administration of EP4 agonist blocked the dissemination of bacteria to sterile tissues (Fig. 
2B). Although pathogenic bacteria spread via the bloodstream usually cause severe systemic 
inflammation, gut leakage of commensal bacteria, especially in patients with damaged gut 
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epithelium or endothelium, may also trigger systemic inflammation. We therefore tested whether 
these disseminated bacteria contribute to indomethacin-augmented systemic inflammation by 
treating mice with indomethacin and antibiotics, known to effectively deplete gut bacteria (19). 
Antibiotic therapy reduced indomethacin-facilitated systemic inflammation (Fig. 2, C to F). 
Indomethacin-dependent systemic inflammation was also observed in Rag1-/- mice (fig. S2), and 
this was again diminished by EP4 agonism (Fig. 2, G to I). Thus PGE2-EP4 signaling prevents 
systemic inflammation independently of adaptive immune cells. 
 
Given that IL-22 has recently been shown to inhibit inflammatory responses, particularly in the 
intestine (19-22), we hypothesized that IL-22 may mediate PGE2 control of systemic inflammation. 
To test this hypothesis, we first examined the effect of PGE2 on IL-22 production. Mice treated 
with indomethacin reduced LPS–induced IL-22 production (Fig. 3A), which was mimicked by an 
EP4 antagonist (Fig. 3B). Thus PGE2-EP4 signaling promotes IL-22 production in vivo. While 
LPS-induced systemic inflammation in WT mice was worsened and prevented by indomethacin 
and EP4 agonist, respectively (Fig. 1, G to I), both had little effects on LPS-induced inflammation 
in IL-22-deficient mice (ref. 23) (Fig. S3). Thus IL-22 is required for coupling PGE2-EP4 
signaling-dependent control of systemic inflammation. Furthermore, co-administration of 
recombinant IL-22 (rIL-22) reduced indomethacin–induced bacterial dissemination, which 
positively correlated with reduced systemic inflammation (Fig. 3, C to E), implying that IL-22 
mediates PGE2 suppression of gut bacterial dissemination and subsequent systemic inflammation.  
 
As both PGE2 and IL-22 can potentially protect the gut epithelial barrier (17-22), we reasoned that 
inhibition of bacterial dissemination by PGE2 may act through augmenting IL-22 action on gut 
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epithelial cells. We therefore examined gene expression related to barrier function in intestinal 
tissues. Indomethacin not only suppressed expression of IL-22 but also its receptors, i.e., Il22ra1 
(encoding IL-22Rα1) and Il10rb (encoding IL-10Rβ), and their suppression was prevented by rIL-
22 (Fig. 3F), suggesting that PGE2 may strengthen IL-22–IL-22R signaling in intestinal epithelial 
cells. Indeed, IL-22R–target genes such as Reg3b, Reg3g, Fut2 (24), mucins and tight junctions 
were similarly down-regulated by indomethacin but rescued by rIL-22 (Fig. 3G and fig. S4). 
Expression of genes related to IL-22R signaling and barrier function inversely correlated with gut 
bacterial dissemination (Fig. 3E). Given the protective role of PGE2 in acute colonic mucosal 
injury (17), we proposed that this protection is mediated by IL-22. Indeed, indomethacin worsened 
dextran sulfate sodium (DSS)-induced colitis and this was rescued by rIL-22, which elicited 
significantly less colitis disease activity index measured by weight loss, diarrhea and rectal 
bleeding (Fig. 3H-J). Our results thus indicate an important role of PGE2 in regulating the 
intestinal epithelial barrier function through innate IL-22 signaling. 
 
Flow cytometric analysis showed that IL-22-producing cells were CD45LowLineage(Lin)-
CD90.2+RORγt(retinoid acid receptor-related orphan receptor gamma)+CCR6(CC chemokine 
receptor 6)+ type 3 innate lymphoid cells (ILC3s, ref. 22) in the gut and CD45+Lineage-
CD90.2+CD4+ ILC3s in the spleen (fig. S5). We wondered whether these cells are involved in 
EP4-dependent control of systemic inflammation. Although Rag1-/- mice co-treated with 
indomethacin and an EP4 agonist (i.e., lacking PG signaling except through EP4) did not develop 
systemic inflammation (Fig. 2, G to I), depletion of CD90.2+ ILCs restored indomethacin-induced 
systemic inflammation in these mice (Fig. 4A). To address whether PGE2–EP4 signaling 
specifically in ILCs controls systemic inflammation, we crossed CD90.2-Cre mice (25) with EP4-
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floxed mice (26) to generate tamoxifen-induced selective down-regulation of EP4 in CD90.2+ cells 
(including T cells and ILCs) in heterozygous CD90.2CreEP4fl/+ mice (Fig. 4B). CD90.2CreEP4fl/+ 
mice produced less IL-22 in response to LPS, which was associated with augmentation of systemic 
inflammatory response, e.g., TNF-α production (Fig. 4B), while down-regulation of EP4 in T cells 
(27) affected neither IL-22 nor TNF-α production (fig. S6). These data demonstrate that PGE2-
EP4 signaling controls systemic inflammation, at least in part, through the regulation of ILC3s. 
 
Next, we investigated the impact of PGE2 on ILC3 maintenance. Indomethacin significantly 
diminished ILC3 numbers in the gut and spleen at the steady state (Fig. 4C and fig. S7, A to C). 
This reduction was prevented by an EP4 agonist and was mimicked by an EP4 antagonist (Fig. 4C 
and fig. S7). Consistently, ILC3s express PGE2 receptors with especially high expression levels 
of EP4 (fig. S8). Furthermore, indomethacin down-regulated Ki-67 expression and an EP4 agonist 
prevented this reduction in ILC3s (Fig. 4D), suggesting that PGE2-EP4 signaling potentiates ILC3 
proliferation. PGE2-EP4 signaling also prevented ILC3 apoptosis in vitro but it had little effect on 
ILC3 apoptosis in vivo (Fig. S9, A and B). Moreover, down-regulation of EP4 in CD90.2+ ILCs 
not only decreased RORγt+ ILC3s but also weakened IL-7 responsiveness, e.g., Bcl-2 expression, 
in ILC3s (Fig. S9C). To further understand the effect of PGE2 on ILC3s, we measured gene 
expression by quantitative polymerase chain reaction in Lin-CD45lowCD90.2hiKLRG1-CCR6+ 
ILC3s sorted from small intestines of mice treated with indomethacin and EP4 agonist. PGE2-EP4 
signaling up-regulates many ILC3 signature genes including Rorc, Il23r, Il1r1, Il22, Il17a, Lta, 
Ltb, Tnfsf11 and Tnfsf4 as well as Bcl2l1 (Fig. 4E).  
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We next asked whether and how PGE2 regulates ILC3 function. PGE2 promoted IL-23-driven IL-
22 production by gut lamina propria leukocytes isolated from Rag1-/- mice in vitro (Fig. 4, F and 
G) and this was inhibited by indomethacin (Fig. 4H). PGE2 also promoted IL-22 production from 
splenic CD4+ ILC3s, which was mediated by EP2 and EP4 (fig. S10, A to C). More importantly, 
PGE2 increased IL-23-driven IL-22 production from highly purified CD45
+Lin-CD90.2+KLRG1-
CCR6+ ILC3s from intestines and CD3-CD11b-CD11c-CD4+ ILC3s from spleen or bone marrow 
(Fig. 4I and fig. S10D), suggesting a direct action of PGE2 on ILC3s. In addition, PGE2 also 
increased IL-22 production from ILC3s in response to IL-1β and IL-7 (fig. S11). PGE2 activated 
cyclic adenosine monophosphate signaling in ILC3s and in turn enhanced IL-22 production (Fig. 
4J and fig. S12, A and B). Moreover, PGE2-augmented IL-22 production depended on the 
transcription factor signal transducer and activator of transcription 3, which is critical for IL-22 
production by ILC3s (28), but not RORγt or Ahr (fig. S12, C to E). Altogether, these data 
demonstrate that PGE2–EP4 signaling promotes ILC3 homeostasis and IL-22 production through 
promoting ILC3 proliferation and enhancing cytokine (e.g., IL-7, IL-23 and IL-1) responsiveness. 
 
Finally, we questioned whether PGE2 promotes IL-22 production from human ILC3s. To answer 
this, we sorted human Lin-CD161+CD127+CD117+CRTH2- ILC3s from periphery blood of 
healthy donors and cultured them with IL-2, IL-23 and IL-1β to induce IL-22 production. Addition 
of PGE2 similarly up-regulated IL-22 production from sorted human ILC3s (Fig. 4K). Moreover, 
expression of the human IL22 gene in healthy individuals infused with a bacterial endotoxin (ref. 
29) positively correlated with expression of PTGS2 and PTGES (encoding mPGES-1) (fig. S13); 
two inducible enzymes that mediate PGE2 synthesis (4). Acute pancreatitis (AP) is a sterile initiator 
of systemic inflammation that results in multiple organ dysfunction where gut barrier injury is 
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central to the pathogenesis (30). Given that IL-22 was protective in an animal model of AP (31), 
we measured IL-22 levels in patients with AP. IL-22 concentrations in plasma were lower in 
patients with AP compared to healthy controls at the time of admission to hospital (Fig. 4L), 
further confirming that the reduction of IL-22 signaling is associated with development of systemic 
inflammation. 
 
In summary, we identify a physiological role of endogenous PGE2–EP4 signaling in activating the 
ILC3/IL-22 axis, which functionally contributes to crosstalk between the innate immune system, 
gut epithelium and microflora, and subsequently constrains systemic inflammation (fig. S14). 
These findings provide valuable insight towards understanding how inactivation of COXs may be 
harmful in severe bacterial infection and inflammation (32-34) and advance a crucial cellular and 
molecular mechanism for a scenario in which maintaining or augmenting PGE2 signaling, e.g., by 
inhibiting the PGE2-degrading enzyme 15-PGDH, protects intestinal barrier injury and potentiates 
its repair and control of systemic inflammation (35, 36).  
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Fig. 1. PGE2–EP4 signaling controls LPS–induced systemic inflammation. (A) Gene 
expression of PTGES2 and PTGER4 in whole blood samples of neonates suffering from sepsis 
with confirmed bacterial infection (Red, n=27) and matched non-infection controls (Blue, n=35). 
Line graphs display gene expression (Log2 scale) as probability density plots for both group 
samples. Non-parametric Wilcoxon-Rank-Sum tests (Pdiff) were used to test for differential 
expression of a gene between infected and control neonates. Fligner-Killeen tests (Pvar) were used 
to test if sepsis and control groups have substantively different inter-subject variation in gene 
expression levels. (B) Supervised heat map of clinical neutrophil counts and expression levels for 
PTGES2 and PTGER4 genes for non-infected healthy controls (n=12) and bacterially infected 
neonates (n=27). Colored scale bar is shown for neutrophil count or gene expression z-score 
transformed values, respectively. ***P<0.001 by non-parametric Spearman correlation test 
performed to analyze the negative association between PTGES2 (rs=-0.6111) or PTGER4 (rs=-
0.6323) gene expression and blood neutrophil counts. (C to F) Serum levels of TNF-α and IL-6 
(C), spleen size and weight (D), neutrophil counts in peritoneal cavity lavage (E) and liver 
histology (F) of WT C57BL/6 mice treated with indomethacin (Indo) or vehicle control (Veh) for 
5 d followed by LPS challenge injection for another 2 (C, n=6 per group) or 24 h (D to F, n=8 per 
group). (G to I) Spleen weight (G), neutrophils (H) and serum levels of TNF-α and IL-6 (I) of WT 
C57BL/6 mice treated with indomethacin and agonists for EP2 or EP4 followed by LPS challenge 
for 24 (G and H) or 2 h (I). Data shown as means  SEM are pooled from two independent 
experiments. Scale bar, 50 μm. *P<0.05, **P<0.01 by one-way ANOVA. NS, not significant; ND, 
not detected. 
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Fig. 2. PGE2 control of systemic inflammation involves gut bacterial dissemination and acts 
independently of adaptive immune cells. (A) Colony forming units (CFU) present in liver 
homogenates from WT C57BL/6 mice (n=6) treated with indomethacin for 5 d followed by LPS 
challenge for another 24 h. (B) CFU present in liver homogenates from WT C57BL/6 mice treated 
with indomethacin plus administration of an EP4 agonist (n=6) or vehicle (n=8) for 5 d followed 
by LPS challenge for another 24 h. (C to F) Spleen size and weight (C), neutrophils (D), liver 
histology (E) and serum levels of TNF-α and IL-6 (F) of WT C57BL/6 mice (n=6 per group) 
treated with indomethacin and antibiotics (ABX) for 5 d followed by LPS challenge for another 
24 (C to E) or 2 h (F). (G to I) TNF-α and IL-6 levels in serum (G) and peritoneal cavity lavage 
(H) and CFU present in liver homogenates (I) from Rag1-/- mice treated with indomethacin plus 
administration of an EP4 agonist or vehicle control (n=8 per group) for 4 d. Data shown as means 
 SEM are pooled from two independent experiments. Scale bar, 50 μm. *P<0.05, **P<0.01, 
***P<0.001 by two-way ANOVA (C, D and F) or Mann-Whitney test (G to I). ND, not detected.  
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Figure 3. IL-22 mediates PGE2 protection against systemic inflammation and intestinal 
barrier injury. (A) Serum IL-22 levels of WT C57BL6 mice treated with indomethacin (Indo, 
n=6) or vehicle control (Veh, n=6) for 5 days followed by challenge with LPS or PBS for 2 h. (B) 
Serum IL-22 levels in WT C57BL/6 mice treated with an EP4 antagonist or vehicle (n=4 per group) 
in drinking water for 5 d followed by LPS challenge for another 2 h. (C to G) Rag1-/- mice were 
treated with vehicle (Veh, n=9) or indomethacin (Indo) plus administration of rIL-22 (n=10) or 
vehicle control PBS (n=10) for 4 d. (C) CFUs present in liver homogenates; (D) neutrophil counts; 
(E) correlation of liver CFU with systemic inflammation profile and expression profile of genes 
related to intestinal barrier function; (F and G) gene expression of IL-22 and its receptors (F) and 
antimicrobial peptides (G) in the terminal ileum. Expression was measured by real-time PCR, 
normalized to Gapdh gene and presented as relative expression (in Log2 Fold Change) to the 
vehicle control group. (H to J) Change in body weight (H), disease activity index (I) and colon 
length (J) of WT C57BL/6 mice (n=10 per group) treated with 2% DSS and indomethacin or 
vehicle control in drinking water plus administration of rIL-22 or vehicle control PBS for 6 days. 
Data shown as means  SEM are pooled from two (A, H, I and J) or three (C to G) independent 
experiments or represent one experiment (B). *P<0.05, **P<0.01, ***P<0.001 by Mann-Whitney 
test (A, B and D), one-way ANOVA (C, F to J) or two-tailed Pearson correlation test (E). 
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Fig. 4. PGE2–EP4 signaling potentiates ILC3 homeostasis and function that contributes to 
control of systemic inflammatory response. (A) Splenic CD90.2+ ILCs, serum TNF-α levels in 
and neutrophil counts in Rag1-/- mice co-treated with indomethacin and an EP4 agonist plus anti-
CD90.2 (αCD90.2) or control IgG antibodies (n=8 per group) for 4 days. (B) Expression of Ptger4 
mRNA in splenic CD90.2+ cells and serum levels of IL-22 and TNF-α in tamoxifen-treated 
CD90.2CreEP4fl/+ mice (n=7) and control C57BL/6 mice (n=5) at 1.5 h after LPS challenge. (C-E) 
Rag1-/- (C,D) or C57BL/6 (E) mice were treated with indomethacin with or without an EP4 agonist 
for 4-5 d. (C) Percentages and numbers of ILC3s in small intestines. Cells were ex vivo stimulated 
with IL-23 for 3 h. Each point represents an individual mouse. (D) Ki-67 expression in gut ILC3s. 
Each point represents an individual mouse. (E) Gene expression profile in gut ILC3s presented as 
relative expression to the vehicle control group. Data are the summary of two independent 
experiments with 8 mice for each group. (F) Expression of RORγt and IL-22 by Rag1-/- gut CD45+ 
lamina propria leukocytes (LPLs) stimulated with IL-23 and PGE2 for 4 h. Numbers in brackets 
represent IL-22 MFI of the RORγt+IL-22+ populations. (G to J) IL-22 production in supernatants 
by LPLs or ILC3s isolated from small intestines of Rag1-/- mice and then cultured with indicated 
conditions overnight (G, H, J) or for 3 d (I). (K) IL-22 production by human ILC3s cultured with 
IL-2, IL-23, IL-1β and PGE2 for 4 d (n=5 donors). (L) Plasma IL-22 levels in individuals with 
acute pancreatitis (AP) at the time of presentation to hospital (n=48) or from healthy individual 
donors (n=28). Horizon line represent the mean for each group. Data shown as means  SEM are 
pooled from two or more independent experiments (A, C to E, G, J and K) or represent one (B) or 
two (F, H, I) independent experiments. *P<0.05, **P<0.01, ***P<0.001 by unpaired Student’s t-
test (A, B, H and I), one-way ANOVA (C, D, F, G and J), ratio paired t-test (K) or Mann Whitney 
test (L). 
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Materials and Methods 
Mice. 
Wild-type C57BL/6 mice were purchased from Harlan UK. To generate mice with 
selective EP4 deficiency in CD90.2+ ILCs, CD90.2(Thy1.2)-Cre mice on C57BL/6 
background (25) were crossed to lox-flanked Ptger4 (EP4-floxed) mice on C57BL/6 
background (26). EP4-floxed mice were also crossed with Lck-Cre mice (on C57BL/6 
background) to generate mice with selective EP4 deletion in T cells (27). All gene-
modified mice including C57BL/6 Rag1-/- and IL-22-/- mice were bred and maintained 
under specific pathogen-free conditions in accredited animal facilities at the University of 
Edinburgh. Mice were aged >8 weeks old at the beginning of use and sex-matched. Both 
male and female mice were used in experiments. Mice were analyzed individually and no 
mice were excluded from the analysis, with the exception of exclusions due to technical 
errors in preparation of intestinal LPLs and failure of induction of Cre recombination by 
tamoxifen. All experiments were conducted in accordance with the UK Scientific 
Procedures Act of 1986 and had local ethical approval. 
 
Treatment with small compounds, antibiotics, antibodies and rIL-22. 
When indicated, mice were treated with indomethacin (5 mg/kg body weight/d, Sigma) or 
vehicle control (0.5% EtOH) in drinking water for 4-6 consecutive days for WT 
C57BL/6, Rag1-/- and IL-22-/- mice. In some experiments, mice were co-treated by 
intraperitoneal (i.p.) injection with an EP2 selective agonist (butaprost, Cayman) or an 
EP4 selective agonist (L-902,688, Cayman) at the dose of 10 µg per injection (one 
injection daily for 5 consecutive days) together with indomethacin from the starting day. 
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0.5% EtOH in PBS was used as vehicle control. As indicated, mice were treated with an 
EP4 selective antagonist (L-161,982 from Abcam, 10 mg/kg body weight/d) or vehicle 
control (0.5% DMSO) in drinking water for 6 consecutive days or through i.p. injection 
(20 µg per injection, one injection daily; vehicle control, 2% DMSO in PBS) for 5 
consecutive days. To deplete ILCs, an anti-CD90.2 antibody (clone 30H12, BioXcell) or 
a rat IgG2b isotype control antibody (BioXcell) was injected i.p. into Rag1-/- mice at the 
dose of 250 µg per mouse every 3 days. Depletion efficiency was confirmed by flow 
cytometry. Recombinant IL-22 (PeproTech) was intravenously (i.v.) injected into Rag1-/- 
mice at the dose of 500 ng per mouse (one injection daily for 4 consecutive days) from 
the beginning of experiments. Control mice were injected i.v. with PBS. For antibiotic 
therapy, a cocktail of antibiotics containing ampicillin (0.5 mg/ml), gentamycin (0.5 
mg/ml), metronidazole (0.5 mg/ml), neomycin (0.5 mg/ml), vancomycin (0.5 mg/ml) 
plus sucralose (4 mg/ml) was used as referenced to a previous report (19). All antibiotics 
were purchased from Sigma and were administrated in drinking water together with 
indomethacin or vehicle for 5 d. When indicated, WT C57BL/6 mice were injected i.p. 
with lipopolysaccharides (LPS, Escherichia coli 0127:B8, Sigma) at a dose of 10 µg per 
mouse on d 5. Blood was withdrawn at 2 h after LPS injection or at the time that mice 
were culled. Serum was isolated following whole blood centrifugation and stored at -
80oC for analysis. In some experiments, mice were sacrificed 24 h after LPS/PBS 
injection and the peritoneal cavity lavaged (3 x 2 ml cold PBS) for neutrophil counts and 
lavage supernatant cytokines measurements. Other tissues such as spleen, liver, small and 
large intestines were then removed for further analysis.  
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Tamoxifen-induced EP4 deletion. 
Induction of Cre recombination in CD90.2CreEP4fl/+ mice by tamoxifen was described in 
a previous report (25). Briefly, Tamoxifen (Sigma) was dissolved in sunflower 
oil/ethanol (10:1 ratio) at 10 mg/ml and injected i.p. into CD90.2CreEP4fl/+ and control 
mice at the dose of 0.18 mg/g body weight/day for 3-5 consecutive days for Fig. 4B. 
Mice were injected i.p. with LPS (10 ug per injection per mouse) at 5 days after the last 
tamoxifen injection and blood was withdraw at 1.5 h after LPS injection. Splenic 
CD90.2+ cells were isolated using EasySepTM Mouse CD90.2 Positive Selection Kit II 
(Stemcell technologies) and Ptger4 gene expression was measured by real-time PCR in 
isolated splenic CD90.2+ cells to confirm the efficiency of conditional EP4 deletion. In 
Fig. S9C, tamoxifen was dissolved in sunflower oil excluding ethanol. Mice received 
tamoxifen by gavage at a dose of 0.18 mg/g body weight/day for five doses over seven 
days and were rested for further 4 days after the last tamoxifen treatment before being 
subjected to analysis. 
 
DSS colitis. 
WT C57BL/6 mice (8-9 weeks old at the beginning of experiments) were administrated 
with 2% (w/v) of dextran sulfate sodium (DSS, MW 36-50kDa, MP Biochemical) 
together with indomethacin (5 mg/kg body weight/d) or vehicle control (0.5% EtOH) in 
drinking water for 6 consecutive days. Recombinant IL-22 or PBS was injected i.p. into 
indicated mice at the dose of 500-1,000 ng per injection (one injection daily for 6 
consecutive days) from the beginning of the experiments. Throughout the experimental 
timeline, mice were weighed and scored daily for a disease activity index (DAI) score to 
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allow for monitoring colitis progression and pathology. The DAI was scored by the 
following system (37). Body weight: 0 (no or <1% weight loss compared to d 0 body 
weight), 1 (1-5% weight loss), 2 (5-10% weight loss), 3 (10-20% weight loss), and 4 
(>20% weight loss); bleeding: 0 (no bleeding), 1 (blood present in/on faeces), 2 (visible 
blood in rectum), and 4 (visible blood on fur); and stool consistency: 0 (well 
formed/normal stool), 1 (pasty/semi-formed stool), 2 (pasty stool with some blood), 3 
(diarrhea that does not adhere to anus), and 4 (diarrhea that does adhere to anus). Mice 
were immediately culled when body weight loss was greater that 25% or the total colitis 
score was 9 or higher.  
 
Liver histology. 
Liver samples were fixed with 10% neutral buffered formalin solution (Sigma), 
embedded in paraffin, and 5 µm sections were used for staining with hematoxylin and 
eosin (H&E). Adjustment of white balance was applied to the entire images. 
 
Bacteria culture. 
Counts of gut bacterial translocation to the liver were performed as described in a 
previous report (19). Briefly, livers were removed under aseptic conditions and 
mechanically homogenized in sterile PBS. Tissue homogenates were serially diluted and 
cultured on LB agar (Sigma) at 37oC for 2 days for subsequent colony counts. 
 
Isolation of intestinal lamina propria cells. 
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Intestinal lamina propria (LP) cells were isolated as described previously (38). In brief, 
mice were culled and their intestines removed and placed in cold PBS. After removing 
any remaining fatty and mesenteric tissues, samples were cut open longitudinally and any 
contents removed before being washed with HBSS buffer containing 2% FCS, and then 
cut into 0.5 cm pieces. Intestines were shaken at 37oC for 15 min in HBSS containing 2 
mM EDTA. After washing with pre-warmed HBSS buffer, intestines were again shaken 
at 37oC for 30 min in HBSS containing 2 mM EDTA followed by wash with HBSS. 
Intestines were then transferred into gentleMACS C tubes (Miltenyi) digested in RPMI 
1640 medium containing 10% FCS, 1% L-glutamine and antibiotics with 1.25 mg/ml 
collagenase IV (Roche) and 30 ug/ml DNase-I (Roche) by shaking at 37oC for 30 min. 
Digested tissues were homogenized by gentleMACS disassociator running the 
programme m_intestine_01 and mashed through 40 µm cell strainer and flushed through 
HBSS containing 2% FCS. After centrifugation, cells were resuspended in complete 
RPMI 1640 medium for counting, staining, culture and/or sorting. 
 
In vitro cell culture. 
MACS sorted small intestinal LP CD45+ cells, FACS sorted intestinal LP CD45+Lin-
CD90.2+KLRG1-CCR6+ ILC3s, total Rag1-/- spleen cells, or FACS sorted splenic/bone 
marrow CD3-CD11b-CD11c-CD4+ ILCs were cultured in completed RPMI 1640 medium 
(Gibco) supplemented with 10% FBS, 2-Mercaptoethanol (50 µM, Gibco), L-glutamine 
(2 mM, Gibco) and antibiotics (Penicillin and Streptomycin, 100 U/ml, Gibco). When 
indicated, recombinant IL-23 (20 ng/ml, eBioscience), IL-1β (20 ng/ml), IL-2 (10 ng/ml), 
IL-7 (10 ng/ml), indomethacin (10 µM, Sigma), PGE2 (10 µM for detection of pCREB 
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and 100 nM for all other experiments except dose-response experiments, Cayman), an 
EP2 agonist butaprost (500 nM, Cayman), an EP4 agonist CAY10598 (500 nM, 
Cayman), an EP2 antagonist PF-04418948 (10 µM, Cayman), an EP4 antagonist L-
161,982 (10 µM, Cayman), db-cAMP (300 µM, Sigma),  3-isobutyl-1-methylxanthine 
(IBMX, 500 µM for spleen cells and 100 µM for gut LPLs, Cayman), H-89 (10 µM, 
Merck), STAT3 inhibitor VI (S31-201, 25 µM, Merck), RORγt inhibitor (SR2211, 10 
µM, Cayman), Ahr inhibitor (CH-223191, 10 µM, Merck) and their respective vehicle 
control (i.e. EtOH or DMSO) or combination of these reagents were added into cell 
cultures. For detecting cytokines in supernatants, cells were cultured for overnight or for 
3 d as indicated in figure legends, and for intracellular staining of IL-22, cells were 
stimulated with IL-23 for 3-4 h in the presence of 0.2% GolgiPlug (BD Bioscience). In 
vitro cell cultures were performed in triplicates and repeated two or more times. 
 
FACS sorting. 
For purifying ILC3s from the small intestine of Rag1-/- mice, CD45+ LP cells were first 
isolated by MACS using mouse CD45 Microbeads (Miltenyi) and then stained with anti-
CD45 eFluor450 or APC-Cy7 (clone 30-F11, eBioscience), anti-CD11c PE (clone N418, 
BioLegend), anti-CD11b PE (clone M1/70, eBioscience), anti-NK1.1 PE (clone PK136, 
eBioscience), anti-CD90.2 FITC or PE-Cy7 (clone 53-2.1, eBioscience), anti-KLRG1 
APC (clone 2F1, eBioscience), anti-CCR6 Brilliant Violet (clone 29-2L17, Biolegend) on 
ice for 30 min. Alive CD45+Lin-(CD11c-CD11b-NK1.1-)CD90.2+KLRG1-CCR6+ ILC3s 
were sorted by FACSAria II (BD Bioscience). For purifying ILC3s from bone marrow 
and spleens of WT C57BL/6 mice, the CD4+ cell population was first isolated by MACS 
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with mouse CD4 MicroBeads (Miltenyi) and then stained with anti-CD3e PE (clone 145-
2C11, eBioscience), anti-CD11b FITC (clone M1/70, BioLegend) and anti-CD4 PerCP-
Cyanine5.5 (clone RM4-5, eBioscience) on ice for 30 min. In some experiments, an anti-
CD11c PE (clone N418, BioLegend) was also used. Alive Lin-(CD3-CD11b-CD11c-
)CD4+ cells were sorted by FACSAria II (BD Bioscience).  
 
Surface and intracellular staining. 
For surface staining, cells were first stained with the Fixable Viability Dye eFluor® 780 
(eBioscience) on ice for 30 min to exclude dead cells. After wash, cells were stained on 
ice for another 30 min with indicated Abs such as anti-CD45 eFlour® 450, anti-CD3e 
PE, anti-CD11c PE, anti-CD11b PE, anti-B220 PE (clone RA3-6B2, eBioscience), anti-
CD90.2 FITC, anti-CD4 PerCP-Cyanine5.5 or APC. Staining with Annexin V was 
performed using the FITC-Annexin V staining kit (Biolegend). For intracellular staining 
of IL-22, cells were stimulated with IL-23 (20 ng/ml) for 3-4 h in the presence of 
GolgiPlug (BD Bioscience). After staining with the Fixable Viability Dye eFluor® 780 
and surface markers, cells were fixed by the BD Cytofix/Cytoperm Fixation buffer (BD 
Bioscience) for 30 min and then stained with anti-human/mouse IL-22 APC (clone 
IL22JOP, eBioscience) in the BD Perm/Wash Buffer on ice for 1 h. For staining of 
RORγt, a Foxp3/Transcription Factor Fix and Staining Buffer (eBioscience) and Anti-
Mouse ROR-γt PerCP-eFluor710 (clone B2D, eBioscience) were used. For staining of 
peritoneal CD11b+Ly-6G+ neutrophils, peritoneal cells were first stained with Fixable 
Viability Dye eFluor® 780 on ice for 30 min. After wash, cells were stained on ice for 
another 30 min with anti-CD45 eFlour® 450, anti-CD11b FITC and anti-Ly-6G (Gr-1) 
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APC (clone RB6-8C5, eBioscience). To stain p-CREB, cells were stimulated with 10 uM 
of PGE2 or vehicle at 37oC for 30 min, then fixed by a Foxp3/Transcription Factor Fix 
buffer (eBioscience) for overnight followed by staining with surface markers and a 
Phospho-CREB (Ser133) XP Rabbit mAb (clone D1G6, Cell Signaling) or a normal 
rabbit IgG for 1 h. After washing, cells were incubated with AF680 Donkey anti-Rabbit 
IgG for another 30 min. To stain pSTAT3, fresh spleen cells from Rag1-/- mice were 
cultured with PGE2 or vehicle for 5 h and then stimulated with IL-23 for 15 min. Cells 
were fixed by the Foxp3/Transcription Factor Fix buffer for overnight followed by 
staining with surface markers and Alexa Fluor 488 Mouse Anti-STAT3(pS727) (clone 
49, BD Bioscience). Flow cytometry was performed on the BD LSRFortessa (BD 
Bioscience) and analyzed by FlowJo software (Tree Star).  
 
Enzyme-linked immunosorbent assay (ELISA). 
For detection of cytokines in serum and supernatants of cell cultures or peritoneal lavage 
fluids, commercial ELISA kits were used according to the manufacturers’ instructions. 
ELISA Ready-SET-Go!® kits for mouse IL-22 and IL-6 were obtained from eBioscience, 
while the Mouse TNF-α ELISA MAXTM Deluxe was purchased from BioLegend. 
 
Gene expression and Real-time PCR. 
RNA purification from sorted ILC3s or homogenized terminal ileum tissues was 
performed by using the Rneasy Mini Kit (Qiagen). cDNA was obtained by reverse 
transcription using the High-capacity cDNA Reverse Transcription Kits (ABI). Samples 
were analyzed by real-time PCR with SYBR Premix Ex Taq II (Tli RNase H Plus) kit 
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(Takara) or GoTaq qPCR Master Mix (Promega) on the Applied Biosystem 7900HT Fast 
machine. Below primers (some were obtained from ref. 39-47) were used. Il22 forward, 
5'-CATGCAGGAGGTGGTACCTT-3'; Il22 reverse, 5'-CAGACGCAAGCATTT 
CTCAG-3'. Il22ra1 forward, 5'-TGCTCTGTTATCTGGG CTACAA-3'; Il22ra1 reverse, 
5'-TCAGGACACGTTGGACGTT-3'. Il10rb forward, 5'-TCTCTTCCACAGCACCT 
GAA-3'; Il10rb reverse, 5'-GAACACCTCGGCCTCCTC-3'. Reg3b forward, 5'-
TGGGAATGGAGTAAAATG-3'; Reg3b reverse, 5'-GGCAACTTCACCTCACAT-3'. 
Reg3g forward, 5'-CCATCTTCACGTAGCAGC-3'; Reg3g reverse, 5'-CAAGATGTCCT 
GAGGGC-3'. Muc1 forward, 5’-GGTTGCTTTGGCTATCGTCTATTT-3’; Muc1 
reverse, 5’-AAAGATGTCCAGCTGCCCATA-3’. Muc3 forward, 5'-CGTGGTCAACT 
GCGAGAATGG-3'; Muc3 reverse, 5'-CGGCTCTATCTCTACGCTCTCC-3'. Fut2 
forward, 5'-TGTGACTTCCACCATCATCC-3'; Fut2 reverse, 5'-TCTGACAGGGTTT 
GGAGCTT-3'. Cldn1 forward, 5'-GAGGGACTGTGGATGTCCTG-3'; Cldn1 reverse, 
5'-ATGCCAATTACCATCAAGGC-3'. Cldn2 forward, 5'-TGAACACGGACCACTGA 
AAG-3'; Cldn2 reverse, 5'-TTAGCAGGAA GCTGGGTCAG-3'. Ocln forward, 5'-
CATAGTCAGATGGGGGTGGA-3'; Ocln reverse, 5'-ATTTATGATGAACAGCCCCC-
3'. F11r forward, 5'-CTGATCTTTGACCCCGTGAC-3'; F11r reverse, 5'-ACCAGACG 
CCAAAAATCAAG-3'. Tjp1 forward, 5'-ACTCCCACTTC CCCAAAAAC-3'; Tjp1 
reverse, 5'-CCACAGCTGAAGGACTCACA-3'. Tjp2 forward, 5'-CGGATTCCAGAC 
AAGGTGTT-3'; Tjp2 reverse, 5'-ATTCACGTTGATTGTGGCTG-3'. Tnfsf11 forward, 
5’-CGCTTCCCGATGTTTCATG-3’; Tnfsf11 reverse, 5’-GGTTAACCAAGATGG 
CTTCTATTACC-3’. Tnfsf4 forward, 5’-GGGAAGGGGTTCAACCCCTGG-3’; Tnfsf4 
reverse, 5’-GAAGAGAGTTGCAGGCAGACA-3’. Il17a forward, 5’-TGTGAAGGTC 
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AACCTCAAAGTC-3’; Il17a reverse, 5’-GAGGGATATCTATCAGGGTCTTCA-3’. 
Il23r forward, 5'-CCAAGTATATTGTGCATGTGAAGA-3', Il23r reverse, 5'-AGCTT 
GAGGCAAGATATTGTTGT-3'. Il1r1 forward, 5’-TGGAACAGAGCCAGTGTCAG-
3’; Il1r1 reverse, 5’-CAGGAGAAGTCGCAGGAAGT-3’. Lta forward, 5’-GTACCCAA 
CAAGGTGAGCAGC-3’; Lta reverse, 5’-CCAGGACAGCCCATCCACT-3’. Ltb 
forward, 5’-ACGCTTCTTCTTGGCTCGC-3’; Ltb reverse, 5’-ACCTCATAGGCGCTT 
GGATG-3’. Il7ra forward, 5’-GGAACAACTATGTAAGAAGCCAAAAACG-3’; Il7ra 
reverse, 5’-AAGATCATTGGGCAGAAAACTTTCC-3’. Ccr6 forward, 5’-CCTCACA 
TTCTTAGGACTGGAGC-3’; Ccr6 reverse, 5’-GGCAATCAGAGCTCTCGGA-3’. Csf2 
forward, 5’-GCATGTAGAGGCCATCAAAGA-3’; Csf2 reverse, 5’-CGGGTCTGCACA 
CATGTTA-3’. Bcl2 forward, 5’-AGTACCTGAACCGGCATCTG-3’; Bcl2 reverse, 5’-
AGGTATGCACCCAGAGTGATG-3’. Bcl2l1 forward, 5’-ATGACCACCTAGAGCC 
TTGGA-3’; Bcl2l1 reverse, 5’-GAAGAGTGAGCCCAGCAGAAC-3’. Ptger4 forward, 
5’-CCTAACCCCACCCTACAGGT-3’; Ptger4 reverse, AGAAGGACGCGTTGAC 
TCC-3’. Gapdh forward, 5’-TGAACGGGAAGCTCACTGG-3’; Gapdh reverse, 5’-
TCCACCACCCTGTTGCTGTA-3’. Expression of genes Rorc (Mm01261022_m1), Ahr 
(Mm00478932_m1), Stat3 (Mm01219775_m1), Id2 (Mm00711781_m1), Tcf7 
(Mm00493445_m1), Zbtb16 (Mm01176868_m1), Tox (Mm00455231_m1), Nfil3 
(Mm00600292_s1) were measured by Taqman Gene Expression Master Mix (Life 
Technologies) with respective primer sets obtained from Life Technologies. Expression 
was normalized to mouse glyceraldehyde-3-phosphate dehydrogenase (Gapdh) and 
presented as relative expression to control group by the 2–ΔΔCt method. 
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Gene expression analysis of neonatal sepsis blood cells. 
Gene transcription levels were measured by transcription microarray in a study by Smith 
et al. (15) on human neonates comparing confirmed bacterial infection (n=27 
independent neonates) with non-infection controls (n=35 independent neonates). 
Processed and normalized data for genes PTGES2 and PTGER4 were retrieved from this 
study and probability density functions computed for each gene, per group. For each 
gene, the hypothesis of differential expression between infected and control neonates was 
tested through a Wilcoxon-Rank-Sum test. A separate hypothesis of different inter-
subject variability was tested for through Fligner-Killeen tests. Data of blood neutrophil 
counts in neonatal sepsis and control patients were retrieved from our previous report 
(15) to complete a new analysis work for investigating their association with PTGES2 
and PTGER4 gene expression by non-parametric Spearman correlation test. 
 
Human ILC3 sort and culture and human IL-22 analysis. 
Human Lin-CD161+CD127+CRTH2-CD117+ ILC3s were sorted from peripheral blood of 
healthy donors. Lineage markers used for sorting included CD1a (clone HI149), CD3 
(clone OKT3), CD14 (clone HCD14), CD34 (clone 581), CD94 (clone DX22), CD123 
(clone 6H6), TCRα/β (clone IP26), TCRγ/δ (clone B1), BDCA2 (201A) and FcεR1 
(clone AER-37). Anti-human CD161 (clone HP-3G10), CD127 (clone A019D5), CD117 
(clone 104D2) and CD294/CRTH2 (clone BM16) were also used. All these Abs were 
obtained from Biolegend except CD294, which was purchased from BD Bioscience. 
Sorted human ILC3s were cultured with recombinant human IL-2 (5 ng/ml, Biolegend), 
human IL-23 (50 ng/ml, R&D system) and human IL-1β (50 ng/ml, Biolegend) for 4 
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days to induce IL-22 production. PGE2 (100 nM) or vehicle was added into the culture 
system from the starting of culture. IL-22 levels in supernatants was measured by Human 
IL-22 ELISA MAX Deluxe (Biolegend). 
 
Acute pancreatitis patients. 
Human plasma samples were obtained with ethical approval and fully-informed consent 
(MREC ref. number 13/SS/0136, United Kingdom). Samples from our clinical archive 
obtained from persons presenting to hospital with acute pancreatitis (AP) over a three-
month continuous period in 2013 (UKCRN ID: 16116) 
(http://public.ukcrn.org.uk/Search/StudyDetail.aspx?StudyID=16116) were included. The 
diagnosis of AP was made according to the Revised Atlanta Criteria 2012 (48), namely 
an elevated serum amylase concentration > 300 IU/L in the context of abdominal pain, 
nausea and/or vomiting. Healthy volunteer blood samples were collected with ethical 
approval and fully-informed consent (REC ref. number 08/S1103/38, United Kingdom). 
Plasma aliquots were stored at -80oC for <2 years with a single thaw before use. IL-22 
concentrations were measured by ELISA as described above. 
 
Statistical analysis. 
All data were expressed as mean ± SEM. Statistical significance between two groups was 
examined by the Student’s t-test or the Mann-Whitney test, while the one-way and two-
way analysis of variance (ANOVA) with Bonferroni’s, Holm-Sidak’s or Newman-Keuls 
multiple comparisons test were used to evaluate multiple groups. Correlation analysis 
Fig. 3E and Fig. S13 was calculated by Pearson’s correlation coefficient (r). Statistical 
 
 
14 
 
work was performed using Prism 6 software (GraphPad) and a P value of less than 0.05 
was considered as significance. 
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Fig. S1. Down-regulation of PGE2-EP4 signaling is associated with development of 
severe systemic inflammatory diseases in humans. (A) A schematic chart indicates 
PGE2 synthesis from arachidonic acid by COX2 (encoding by PTGS2) and degradation 
into biologically inactive 15-keto PGE2 by 15-PGDH (encoding by HPGD). The PGE2 
receptor EP4 (encoding by PTGER4) is also shown. (B) Expression of PTGS2, HPGD 
and PTGER4 in blood cells taken from patients diagnosed with systemic inflammatory 
response syndrome (SIRS, n=12) or healthy control individuals (n=18) on d 1. Data were 
retrieved from the Gene Expression Omnibus dataset GSE40012 (49). (C) Expression of 
PTGS2, HPGD and PTGER4 in blood cells taken from patients with sepsis (n=10) or 
healthy control (n=20). Data were retrieved from the Gene Expression Omnibus dataset 
GSE28750 (50). (D) Expression of PTGS2, HPGD and PTGER4 in blood cells taken 
from normal children (n=18) or children with septic shock (n=67) on d 1. Data were 
retrieved from the Gene Expression Omnibus dataset GSE13904 (51). (E) Expression of 
PTGS2, HPGD and PTGER4 in blood cells taken from healthy individuals (n=37) or 
patients with severe blunt trauma or burn injury (n=205) within 24 h from injury. Data 
were retrieved from the Gene Expression Omnibus dataset GSE36809 (52). *P<0.05, 
**P<0.01, ***P<0.001, ****P<0.0001 by 2-tailed Mann-Whitney test. 
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Fig. S2. Adaptive immune cells are not required for indomethacin-dependent 
systemic inflammation. Rag1-/- mice were treated with indomethacin (n=5) or vehicle 
control (n=4) in drinking water for 4 d. (A) Spleen size and weight. (B) IL-6 and TNF-α 
concentrations in serum. (C) IL-6 and TNF-α concentration in peritoneal cavity lavage 
fluids. (D) Accumulation of CD11b+Ly-6G+ neutrophils in peritoneal cavities. (E) H&E 
staining histological sections of the liver. Data shown as mean ± SEM are pooled from 
two independent experiments. Scale bar, 50 µm. *P<0.05 by the unpaired, 2-tailed 
student t-test. ND, not detected. 
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Fig. S3. IL-22 is required for control of systemic inflammation by PGE2–EP4 
signaling. Spleen size and weight (A), neutrophils in peritoneal cavity (B) and serum 
levels of TNF-α and IL-6 (C) of C57BL/6 IL-22-/- mice treated with indomethacin in 
drinking water plus administration (i.p.) of an EP4 agonist or vehicle control for 5 d 
followed by LPS challenge (i.p.) for another 24 h (A and B) or 2 h (C). Each point 
represents one mouse. Data are pooled from two independent experiments. Scale bar, 0.5 
cm. *P<0.05, **P<0.01 by one-way ANOVA. NS, not significant. 
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Fig. S4. Gene expression profile of intestinal barrier function. Rag1-/- mice treated 
with vehicle (n=9) or indomethacin in drinking water plus administration (i.v.) of rIL-22 
(n=10) or PBS (n=10) for 5 d as in Fig. 3, C to G. (A to C) Gene expression of mucins 
(A), fucosylthransferase 2 (B) and tight junctions (C) in the terminal ileum. Expression 
was normalized to Gapdh gene and presented as relative expression (in Log2 Fold 
Change) to the vehicle/PBS control group. Data shown as means ± SEM are pooled from 
three independent experiments. *P<0.05, **P<0.01 by one-way ANOVA. 
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Fig. S5. Identification of IL-22-producing type 3 innate lymphoid cells in the gut and 
spleen. (A) Intracellular staining of small intestinal lamina propria lymphocytes (LPLs) 
from Rag1-/- mice cultured with IL-23 for 4 h. The result indicates that IL-22-expressing 
innate cells in the gut are CD45+/LowLineage-(CD11c/CD11b/NK1.1)CD90.2+CCR6+ 
RORγt+ ILC3s and most of these cells (>90%) do not express CD4. (B) Intracellular 
staining of total Rag1-/- spleen cells cultured with IL-23 for 4 h. The result indicates that 
all IL-22-expressing innate cells in the spleen are CD45+Lin-CD90.2+ and the majority 
(70-80%) of them are CD4+ ILC3s.  
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Fig. S6. PGE2–EP4 signaling in T cells is not required for control of systemic 
inflammation. Serum levels of IL-22 and TNF-α of mice with specific EP4 deletion in T 
cells (i.e., Lck-EP4 mice mixed of LckCreEP4fl/+ and LckCreEP4fl/fl mice, n=4) and control 
litter mates (mixed of LckCre, EP4fl/fl, EP4fl/+ and EP4+/+ mice, n=8) at 1.5 h after LPS 
challenge. Efficiency of EP4 deletion in T cells of LckCreEP4fl/+ (~50%) and LckCreEP4fl/fl 
(~97%) mice comparing to control mice has been shown previously (27). Data shown as 
means ± SEM are pooled from two independent experiments. P values are calculated by 
unpaired two-tailed Student’s t-test. 
 
 
Co
ntr
ol
Lck
-EP
4
0
50
100
150
Se
ru
m 
IL-
22
 (p
g/m
l) P=0.59
Co
ntr
ol
Lck
-EP
4
0
1
2
3
Se
ru
m 
TN
F-
α 
(n
g/m
l)
P=0.98
LPS
 
 
21 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. S7. PGE2–EP4 signaling regulates innate lymphoid cell homeostasis in spleen. 
(A) Intracellular staining of small intestinal LPLs of C57BL/6 Rag1-/- mice treated with 
vehicle (n=9) or indomethacin in drinking water plus an EP4 agonist (n=8) or vehicle 
(n=10) for 4 days as in Fig.4C. Representative dot plot data show RORγt+IL-22+ cells 
within alive CD45+ populations. (B) Frequencies of CD45+Lin-CD4+ and CD45+Lin-IL-
22+ ILC3s in spleens of Rag1-/- mice treated with indomethacin (Indo, n=8) or vehicle 
(Veh, n=6) for 4 d. (C) Frequencies of CD45+Lin-CD4+ ILC3s in spleen of Rag1-/- mice 
treated with vehicle (n=6) or indomethacin plus administration (i.p.) of agonist for EP2 
(n=6), EP4 (n=6) or vehicle control (n=8) for 4 days. (D) Frequencies of CD45+Lin-
CD90.2+RORγt+ ILC3s in spleen of Rag1-/- mice treated with indomethacin plus 
administration (i.p.) of an EP4 agonist or vehicle control (n=8 per group) for 4 days. (E) 
Frequencies and numbers of CD45+Lin-CD4+IL-22+ ILC3s in spleens of Rag1-/- mice 
treated (i.p.) with an EP4 antagonist (n=10) or vehicle (n=9) for 4 d. Data shown as mean 
± SEM are pooled from two independent experiments. *P<0.05, **P<0.01, ***P<0.001 
by Mann-Whitney test (B, D and E) or one-way ANOVA (C). 
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Fig. S8. Expression of PG receptors by ILC3s. Gene expression of PG receptors in 
FACS-sorted ILC3 populations isolated from various tissues including splenic Lin-
CD90.2+CD25+CD4+ ILC3s/LTis (Lymphoid tissue inducer cells, n=4), small intestinal 
LP (si-LP) CD45+Lin-NKp46+RORγthi ILC3s (n=3), and mesenteric lymph node (mLN) 
Lin-CD90.2+CD127+CCR6+ST2- ILC3s (n=4). Gene expression in lymph node (LN) 
TCR+CD4+CD8-CD25-CD62hiCD44low naïve T cells (n=2) was used as control. Results 
suggest that in ILC3s the PGE2 receptor EP4 (encoded by Ptger4) is the most expressed 
among 8 subtypes of PG receptors. While ILC3s may also express PGE2 receptors EP1 
(encoded by Ptger1) and EP2 (encoded by Ptger2) and thromboxane A2 receptor TP 
(encoded by Tbxa2r), ILC3s are unlikely to express PGD2 receptor DP (encoded by 
Ptgdr), PGE2 receptor EP3 (encoded by Ptger3), PGF2α receptor FP (encoded by Ptgfr) 
and PGI2 receptor IP (encoded by Ptgir). Data were retrieved from the Gene Expression 
Omnibus dataset GSE37448 for LN CD4+ T cells and si-LP RORγt+ ILC3s (53), 
GSE46468 for splenic CD4+ ILC3s/LTis (54), and GSE67076 for mLN CCR6+ ILC3s 
(55). 
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Fig. S9. PGE2 prevents ILC3 apoptosis and augments IL-7 responsiveness in vitro. 
(A) Expression of Annexin V in CD45+Lin-CD90.2+CCR6+ ILC3s from mesenteric 
lymph nodes of C57BL/6 mice treated with vehicle (n=4) or indomethacin in drinking 
water plus an EP4 agonist (n=7) or vehicle (n=5) for 5 days. (B) Mesenteric lymph node 
cells of Rag1-/- mice were cultured in vitro with indomethacin in the presence or absence 
of PGE2 for 24 h. Data showing expression of Annexin V in CD45+Lin-CD90.2+CCR6+ 
ILC3s are representative of two independent experiments. (C) Mesenteric lymph node 
cells from tamoxifen-treated CD90.2CreEP4fl/+ (n=8) or control (n=7) mice were cultured 
in vitro with IL-7 for 24 h. Expression of Bcl-2 and RORγt in CD45+Lin-CD90.2+ ILCs 
were shown. *P<0.05, **P<0.01 by two-tailed unpaired Student’s t-test. 
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Fig. S10. PGE2 promotes IL-22 production from splenic ILC3s via EP2 and EP4 
receptors in vitro. (A) IL-22 levels in supernatants of total Rag1-/- spleen cells cultured 
with IL-23 and PGE2, indomethacin or EP2 antagonist plus EP4 antagonist overnight. (B) 
Intracellular IL-22 expression in Lin-(CD3-B220-Ter119-CD11c-)CD4+ cells of Rag1-/- 
spleen cells cultured under indicated conditions for 4 h. (C) IL-22 levels in supernatants 
from total Rag1-/- spleen cells cultured with IL-23 without or with indomethacin plus 
agonists and/or antagonists for EP2 or EP4 as indicated overnight. (D) IL-22 production 
by Lin-CD4+ ILC3s sorted from spleen and/or bone marrow and then cultured with IL-23 
in the presence or absence of PGE2 for 3 d. Data shown as means ± SEM are 
representative of two (B-D) or three (A, right) or pooled from five (A, left) independent 
experiments. *P<0.05, **P<0.01, ***P<0.001 by one-way ANOVA (A right, B and C), 
unpaired (D) or paired (A left) Student’s t-test or. ND, not detected. 
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Fig. S11. Cytokine response of ILC3s regulated by PGE2. IL-22 levels in supernatants 
of LPLs isolated from small intestines of Rag1-/- mice and then cultured with indicated 
cytokines in the presence or absence of PGE2 overnight (A) or for 3 days (B). Data 
shown as means ± SEM are pooled from 2-3 independent experiments. For the panel A, 
n=6-7 biological replicates and for the panel B, n=4 biological replicates. *P<0.05, 
**P<0.01 by 2-way ANOVA (A) or unpaired Student’s t-test (B).  
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Fig. S12. Cyclic AMP-PKA and IL-23-STAT3 (transcription factor signal 
transducer and activator of transcription) signaling pathways mediate innate IL-22 
production in vitro. (A) Intracellular expression of phosphorylated CREB (pCREB) in 
splenic CD45+Lin-CD90.2+ ILCs and CD45+Lin-CD90.2+CD4+ ILC3s stimulated with 
PGE2 or vehicle for 30 min. MFI, mean fluorescence intensity. Data shown as means ± 
SEM are representative of two independent experiments. (B) IL-22 production in 
supernatants from total Rag1-/- splenocytes cultured with IL-23 plus db-cAMP or IBMX 
with or without H-89 overnight. db-cAMP, dibutyryl-cAMP; IBMX, 3-isobutyl-1-
methylxanthine. Data shown as means ± SEM are representative of two independent 
experiments. (C) Intracellular expression of phosphorylated STAT3 (pSTAT3) in splenic 
CD45+Lin-CD90.2+CD4+ ILC3s stimulated with PGE2 or vehicle for 5 h and then 
restimulated with IL-23 for a further 15 min. Data shown as means ± SEM are pooled 
from three independent experiments. (D) IL-22 production in supernatants from small 
intestinal LPLs of Rag1-/- mice cultured with IL-23 with or without PGE2 and a STAT3 
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inhibitor overnight. Data shown as means ± SEM (n=5 biological replicates). (E) IL-22 
production in supernatants from total Rag1-/- splenocytes cultured with IL-23 with or 
without db-cAMP and RORγt inhibitor (RORc i) or Ahr inhibitor (Ahr i) overnight, 
suggesting that neither RORγt nor Ahr is likely needed for cAMP-enhanced IL-22 
production. Data shown as means ± SEM are representative of four independent 
experiments. *P<0.05, **P<0.01, ***P<0.001 by one-way ANOVA. 
 
 
28 
 
 
 
 
 
 
 
 
 
 
 
Fig. S13. Positive correlations between gene expression of IL22 and PGE2 synthases 
in response to endotoxin infusion in humans. Expression of IL22 (encoding human IL-
22), PTGS2 (encoding human COX2) and PTGES (encoding human mPGES) genes in 
peripheral blood leukocytes obtained from healthy individuals before or after (2-24 h) 
infusion with endotoxin (CC-RE-Lot 2) or 0.9% sodium chloride (29). Raw data were 
retrieved from the Gene Expression Omnibus dataset GSE3284 (29). Data shown here 
were presented as the ‘Log2Ratio’ of post-infusion (2, 4, 6, 9, 24 h) vs pre-infusion (0 h) 
of the endotoxin. Statistical analysis was calculated by the Pearson correlation 
coefficients (r). 
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Fig. S14. A proposed model. PGE2, produced by many types of cells such as 
macrophages, dendritic cells and gut epithelial cells, through the EP4 receptor contributes 
to maintaining ILC3 homeostasis. PGE2 also works together with IL-23 to promote IL-22 
production by ILC3s. The PGE2/EP4/ILC3/IL-22 axis protects intestinal epithelial barrier 
function through amplification of IL-22-IL-22R signaling and promotion of production of 
antimicrobial peptides, mucus family proteins and tight junctions. This enables 
prevention of peripheral bacterial dissemination and subsequently contributes to control 
of systemic inflammation. 
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